Quantcast

Health Care Sector Update for 11/21/2016: IMUC,OGEN,ACOR


Shutterstock photo

Top Health Care Stocks

JNJ -0.39%

PFE +0.37%

MRK +0.05%

ABT +0.27%

AMGN +0.51%

Health care stocks were mostly higher today, with the NYSE Health Care Index climbing nearly 0.2% while shares of health care companies in the S&P 500 were up nearly 0.4% as a group.

In company news, ImmunoCellular Therapeutics Ltd ( IMUC ) rallied on Monday after the biotech company reported additional survival data supporting its ICT-107 drug candidate in patients with certain forms of brain cancer.

Among patients with newly diagnosed glioblastoma, the Phase II data indicated a survival advantage for the ICT-107 treated group compared to the control group as well as also showing an association between immune response and survival, particularly in the target population for the the ongoing phase 3 registration trial. The data was presented at at a pair of oral sessions at the Society for Neuro-Oncology annual scientific meeting on Nov. 18 in suburban Phoenix.

IMUC shares recently were up more than 12% at $2.94 The company on Nov. 18 effected a 40-to-1 reverse stock split to regain compliance with the New York Stock Exchange minimum bid price rule.

In other sector news,

(+) OGEN, (+18.6%) FDA grants Fast Track designation to the company's AG013 drug candidate. Discloses plans to file investigative new drug application for the prospective treatment for oral mucositis and beginning a Phase II study of AG013 during Q1.

(-) ACOR, (-6.3%) Company discontinues development of dalfampridine drug candidate after it fails to show sufficient efficacy during recent clinical testing to improve walking difficulty in patients.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.



This article appears in: Investing , US Markets
Referenced Symbols: IMUC , OGEN , ACOR



More from MT Newswires

Subscribe






MT Newswires
Contributor:

MT Newswires

Market News, Commodities










Research Brokers before you trade

Want to trade FX?